BAX · Q2 2025 Earnings

Cautious

Baxter International

Reported July 31, 2025

30-second summary

Baxter cut full-year operational sales growth guidance to 3–4% from 4–5% after voluntarily pausing shipments of the Novum LVP infusion pump and conceding that hospital IV-fluid conservation is likely to remain at first-half levels through year-end. Q2 revenue grew 4% YoY to $2.81B with adjusted EPS of $0.59 (+28% YoY), and adjusted operating margin of 15.1% actually expanded 180bps YoY — the pressure point is the FY guide of 15–16%, which requires meaningful H2 expansion off that Q2 base. This is a defensive quarter; management's prepared remarks framed the second-half outlook as a "prudent" downside case.

Headline numbers

EPS

Q2 FY2025

$0.59

Revenue

Q2 FY2025

$2.81B

+4.0% YoY

Gross margin

Q2 FY2025

35.3%

Operating margin

Q2 FY2025

6.8%

Key financials

Q2 FY2025

Metric	Q2 FY2025	YoY
Revenue	$2.81B	+4.0%
EPS	$0.59	—
Gross margin	35.3%	—
Operating margin	6.8%	—

Guidance

Prior quarter data unavailable — comparison not possible.

Segment KPIs

Q2 FY2025

Segment	Q2 FY2025	YoY
Medical Products & Therapies	$1.32B	—
Healthcare Systems & Technologies	$0.767B	+3.0%
Pharmaceuticals	$0.612B	+2.0%
Infusion Therapies & Technologies Sales	$1.024 billion	—
Advanced Surgery Sales	$296 million	—
Drug Compounding Sales	$280 million	—
Care & Connectivity Solutions Sales	$474 million	—

Other KPIs

Q2 FY2025

Segment	Q2 FY2025	YoY
U.S. Sales	$1.536B	+3.0%
International Sales	$1.274B	+6.0%
Adjusted Diluted EPS from Continuing Operations	$0.59	—
Adjusted Operating Income	$423 million	—
Operational Sales Growth	1%	—
Adjusted Gross Margin	40.7%	—

Management tone

Baxter's prepared remarks marked a clear pivot from "execution on track" to "prudent downside assumptions." The defensive framing was unusually explicit for this management team.

IV-solutions recovery has stopped being a recovery story. Through prior quarters Baxter had framed North Cove and the broader IV fluid situation as normalizing. This quarter management conceded conservation is sticking: "the low end of our guidance range assumes conservation levels remain similar to the first half of the year." The shift signals that hospital purchasing behavior has not eased, not that supply is the constraint.

Novum LVP went from growth driver to indefinite pause. Management voluntarily halted shipments and installations of the Novum LVP pump pending quality corrections, and "the low end of our guidance assumes we don't resume shipments for Novum prior to the end of the year." Framing the pause as mission-driven — "we are handling this situation with our mission in mind and with the utmost priority, speed, and care" — keeps the language defensive without quantifying the severity of the quality issues or the lost revenue.

"Prudent" framing replaced confidence. The CFO's stated rationale for the walk-down — capturing "more of the potential downside risks associated with some of the factors we've discussed today, primarily around infusion pumps and fluid conservation" — signals that visibility into the back half is poor and that Baxter is now guiding to a downside case rather than a recovery.

Recurring themes management leaned on this quarter:

Voluntary pause on Novum LVP shipments due to quality feedback and field actionsPersistent IV fluid conservation by hospitals despite supply stabilizationDownward revision of full-year operational growth guidance from 4-5% to 3-4%Unexpected softness in U.S. injectables and elevated IV push protocols post-hurricaneOperating margin compression from volume absorption and product mix headwindsTariff impact reduction from $60-70M to $40M assumption

Risks management surfaced:

Novum LVP field actions affecting small subset of clinical use cases requiring interim mitigationsHospital IV fluid conservation efforts not materializing as expected despite improved supplyU.S. patient admission levels remaining below previous expectationsMacroeconomic uncertainty impacting hospital capital spendingInjectables portfolio weakness from hurricane-induced protocol changes and IV push utilizationTariff impacts remaining dynamic with potential additional pharmaceutical tariffs unquantified

What to watch into next quarter

Novum LVP shipment resumption — management's stated goal is to resume by year-end; if Q3 prints without a resumption date, the low-end FY guide becomes the base case and Q4 sets up for another walk-down.

IV conservation trajectory — watch whether conservation levels show any improvement off the first-half baseline in Q3; persistent or deeper conservation would force further MPT segment cuts into 2026.

U.S. injectables and IV-push utilization — track whether pre-mixed injectables demand recovers or whether the hurricane-induced protocol shift is permanent; this is the unmodeled risk that surprised management this quarter.

Adj. operating margin — FY guide of 15–16% requires H2 expansion off Q2's 15.1% base; watch Q3 margin against that bar.

Tariff assumption — management cut the FY tariff impact to $40M from $60–70M; any reversal (particularly pharmaceutical-specific tariffs flagged as unquantified) would erode EPS.

Sources

Baxter International Q2 2025 press release / 8-K Exhibit 99.1 — https://www.sec.gov/Archives/edgar/data/10456/000162828025036835/bax-20250630xex991.htm
Baxter International Q2 2025 earnings call prepared remarks

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.